US 11,753,481 B2
Bispecific antibodies against CEACAM5 and CD47
Vanessa Buatois, Contamine-Sarzin (FR); Dirk Hose, Pfäffikon (CH); and Anja Seckinger, Lachen (CH)
Assigned to LAMKAP BIO BETA LTD, Schwyz Pfäffikon (CH)
Filed by LamKap Bio Beta AG, Schwyz Pfäffikon (CH)
Filed on Dec. 17, 2021, as Appl. No. 17/554,941.
Claims priority of provisional application 63/135,996, filed on Jan. 11, 2021.
Claims priority of application No. 20215766 (EP), filed on Dec. 18, 2020.
Prior Publication US 2022/0195067 A1, Jun. 23, 2022
Int. Cl. C07K 16/46 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3007 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A bispecific antibody molecule comprising a first binding part that binds specifically to human CEACAM5 and a second binding part that binds specifically to human CD47 wherein:
a) the first binding part comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRH1 is SEQ ID NO:1, CDRH2 is SEQ ID NO:2 and CDRH3 is SEQ ID NO:3,
b) the first binding part comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 are selected from the group consisting of
b1) SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, respectively;
b2) SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, respectively;
b3) SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, respectively;
b4) SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, respectively; and
b5) SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28, respectively; and
c) the second binding part comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRH1 is SEQ ID NO:1, CDRH2 is SEQ ID NO:2 and CDRH3 is SEQ ID NO:3,
and a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein CDRL1 is SEQ ID NO:7, CDRL2 is SEQ ID NO:8, and CDRL3 is SEQ ID NO:9.